Sayantani Sarkar Bhattacharya1,2,3, Prabhu Thirusangu1, Ling Jin1, Julie Staub1, Viji Shridhar4, Julian R Molina5. 1. Department of Experimental Pathology and Laboratory Medicine, Mayo Clinic, Rochester, MN, USA. 2. Department of Medical Oncology, Mayo Clinic, Rochester, MN, USA. 3. Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN, USA. 4. Department of Experimental Pathology and Laboratory Medicine, Mayo Clinic, Rochester, MN, USA. Shridhar.Vijayalakshmi@mayo.edu. 5. Department of Medical Oncology, Mayo Clinic, Rochester, MN, USA. Molina.Julian@mayo.edu.
Abstract
BACKGROUND: Malignant pleural mesothelioma (MPM) is an aggressive neoplasm and often acquires chemoresistance by increasing stemness in tumour tissue, thereby generating cancer stem cells (CSCs). CSCs escape treatment by deploying metabolic pathways to trigger dormancy or proliferation, also gaining the ability to exit and re-enter the cell cycle to hide their cellular identity. METHODS: We employed various cellular and biochemical assays to identify the role of the glycolytic enzyme PFKFB3, by knocking it down and pharmacologically inhibiting it with PFK158, to determine its anticancer effects in vitro and in vivo by targeting the CSC population in MPM. RESULTS: Here, we have identified PFKFB3 as a strategic player to target the CSC population in MPM and demonstrated that both pharmacologic (PFK158) and genetic inhibition of PFKFB3 destroy the FAK-Stat3-SOX2 nexus resulting in a decline in conspicuous stem cell markers viz. ALDH, CD133, CD44, SOX2. Inhibition of PFKFB3 accumulates p21 and p27 in the nucleus by decreasing SKP2. Lastly, PFK158 diminishes tumour-initiating cells (TICs) mediated MPM xenograft in vivo. CONCLUSIONS: This study confers a comprehensive and mechanistic function of PFKFB3 in CSC maintenance that may foster exceptional opportunities for targeted small molecule blockade of the TICs in MPM.
BACKGROUND: Malignant pleural mesothelioma (MPM) is an aggressive neoplasm and often acquires chemoresistance by increasing stemness in tumour tissue, thereby generating cancer stem cells (CSCs). CSCs escape treatment by deploying metabolic pathways to trigger dormancy or proliferation, also gaining the ability to exit and re-enter the cell cycle to hide their cellular identity. METHODS: We employed various cellular and biochemical assays to identify the role of the glycolytic enzyme PFKFB3, by knocking it down and pharmacologically inhibiting it with PFK158, to determine its anticancer effects in vitro and in vivo by targeting the CSC population in MPM. RESULTS: Here, we have identified PFKFB3 as a strategic player to target the CSC population in MPM and demonstrated that both pharmacologic (PFK158) and genetic inhibition of PFKFB3 destroy the FAK-Stat3-SOX2 nexus resulting in a decline in conspicuous stem cell markers viz. ALDH, CD133, CD44, SOX2. Inhibition of PFKFB3 accumulates p21 and p27 in the nucleus by decreasing SKP2. Lastly, PFK158 diminishes tumour-initiating cells (TICs) mediated MPM xenograft in vivo. CONCLUSIONS: This study confers a comprehensive and mechanistic function of PFKFB3 in CSC maintenance that may foster exceptional opportunities for targeted small molecule blockade of the TICs in MPM.
Authors: Anastasiya Y Bobarykina; Dmytro O Minchenko; Iryna L Opentanova; Michel Moenner; Jaime Caro; Hiroyasu Esumi; Oleksandr H Minchenko Journal: Acta Biochim Pol Date: 2006-12-04 Impact factor: 2.149
Authors: Toshiya Atsumi; Jason Chesney; Christine Metz; Lin Leng; Seamas Donnelly; Zenji Makita; Robert Mitchell; Richard Bucala Journal: Cancer Res Date: 2002-10-15 Impact factor: 12.701
Authors: Brian F Clem; Julie O'Neal; Gilles Tapolsky; Amy L Clem; Yoannis Imbert-Fernandez; Daniel A Kerr; Alden C Klarer; Rebecca Redman; Donald M Miller; John O Trent; Sucheta Telang; Jason Chesney Journal: Mol Cancer Ther Date: 2013-05-14 Impact factor: 6.261
Authors: Abdullah Yalcin; Brian F Clem; Alan Simmons; Andrew Lane; Kristin Nelson; Amy L Clem; Erin Brock; Deanna Siow; Binks Wattenberg; Sucheta Telang; Jason Chesney Journal: J Biol Chem Date: 2009-05-27 Impact factor: 5.157